Abstract:Atherosclerosis (AS) leads to atherosclerotic cardiovascular disease (ASCVD), the predominant cause of death worldwide. As traditional lipid-lowering therapies have encountered a bottleneck in dealing with diverse types of atherosclerotic plaques and ASCVD, alternative therapies that can target other mechanisms are urgently needed. Recent studies have revealed that AS is rooted in disrupted immune responses, such as chronic local inflammation and autoimmune responses, and immunotherapies have emerged as a nascent avenue to control plaque development owing to their satisfactory effects and high cost efficiency. The atherosclerotic immune microenvironment (AIME) is the microenvironment in which diverse immune responses occur dynamically. AIME is characterized by persistent inflammatory responses, shifted immunometabolism, and the formation of adventitial neuroimmune cardiovascular interfaces, all of which are regarded as prospective targets for AS immunotherapy. Recently, the advent of nanotechnology has advanced AS immunotherapy targeting the AIME. Manifold nanoplatforms have greatly enriched AS therapeutics owing to their multimodal imaging and multichannel intervention capabilities. Here, we offer an overview of AIME and discuss how nanomedicines can assist in AS diagnosis and intervention. We introduce nanoplatforms integrated with imaging techniques, such as magnetic resonance imaging, photoacoustic imaging, fluorescence imaging, positron emission tomography, and ultrasound imaging, which can target AIME to realize plaque diagnosis. Moreover, we elaborated on nanomaterials that regulate innate immune responses, adaptive immune responses, and aberrant immunometabolism to achieve AIME modulation. Furthermore, we highlight the possible future directions of AS therapeutics, with a focus on AIME-targeted nanomedicines.

Recent progress in biomimetic nanomedicines based on versatile targeting strategy for atherosclerosis therapy

Nanocarrier-Based Targeting of Cluster of Differentiation 44 for Treating Atherosclerosis: A Review

ROS-responsive Biomimetic Nanovesicles to Plaque Microenvironment in Targeted Therapy of Atherosclerosis

Biomimetic Nanoparticles for the Diagnosis and Therapy of Atherosclerosis

Biomimetic nanomedicines for precise atherosclerosis theranostics

Biomimetic nanoparticles targeting atherosclerosis for diagnosis and therapy

Current targeting strategies and advanced nanoplatforms for atherosclerosis therapy

Nanocarrier Based Targeting of Vascular Cell Adhesion Molecule-1 for Diagnosis and Treatment of Atherosclerosis: Current Status and Future Perspectives

Shedding New Light on Atherosclerosis Therapeutics: Nanomedicines Targeting Atherosclerotic Immune Microenvironment

Application of targeted therapy strategies with nanomedicine delivery for atherosclerosis

Nature-inspired nanocarriers for improving drug therapy of atherosclerosis

Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis

Advances in nano-delivery systems based on diagnosis and theranostics strategy for atherosclerosis

Biomimetic nanoparticles: U937 cell membranes based core–shell nanosystems for targeted atherosclerosis therapy

Recent advances in inhibiting atherosclerosis and restenosis: from pathogenic factors, therapeutic molecules to nano-delivery strategies

Cell adhesion molecule-mediated therapeutic strategies in atherosclerosis: From a biological basis and molecular mechanism to drug delivery nanosystems

A Macrophage Membrane-Functionalized, Reactive Oxygen Species-Activatable Nanoprodrug to Alleviate Inflammation and Improve the Lipid Metabolism for Atherosclerosis Management

Biomimetic Nanotherapies: Red Blood Cell Based Core–Shell Structured Nanocomplexes for Atherosclerosis Management

ROS-responsive Biomimetic Nanoparticles for Potential Application in Targeted Anti-Atherosclerosis

Recent Advances in Targeted Stimuli-Responsive Nano-Based Drug Delivery Systems Combating Atherosclerosis

Advances in the treatment of atherosclerosis with ligand-modified nanocarriers